# A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function

> **NCT07694843** · PHASE1 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Participants
- Participants With Mild Hepatic Impairment
- Participants With Moderate Hepatic Impairment

## Interventions

- **DRUG:** ammoxetine hydrochloride enteric-coated tablets

## Key facts

- **NCT ID:** NCT07694843
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694843, "A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*